产品说明书

Vancomycin

Print
Chemical Structure| 1404-90-6 同义名 : 万古霉素
CAS号 : 1404-90-6
货号 : A606050
分子式 : C66H75Cl2N9O24
纯度 : ≥950μg/mg
分子量 : 1449.254
MDL号 : MFCD05664587
存储条件:

粉末 Sealed in dry,2-8°C

液体 -20°C:3-6个月-80°C:12个月

溶解度 :

DMSO: 120 mg/mL(82.8 mM),配合低频超声,并水浴加热至45℃助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

动物实验配方:
生物活性
描述 Vancomycin is one of only a few antibiotics available to treat patients infected with methicillin-resistant Staphylococcus aureus and methicillin-resistant, coagulase-negative Staphylococcus species[3]. Vancomycin inhibits the second stage of cell wall synthesis of susceptible bacteria, alters the permeability of the cell membrane and selectively inhibits ribonucleic acid synthesis. Enhancement of antimicrobial activity has been demonstrated with the combination of vancomycin and an aminoglycoside against Staph. aureus, Str. bovis, enterococci and viridans streptococci. The combination of vancomycin and rifampicin are antagonistic to most strains of Staph. aureus, though indifference and occasionally synergism have been shown, but is synergistic against strains of Staph. epidermidis. It shows indifference against enterococci. Vancomycin and fusidic acid are indifferent against Staph. Aureus[4]. Vancomycin improved clinical scores and histopathology acutely but was associated with poor outcome posttreatment in C. difficile-infected mice. Decreasing vancomycin exposure may decrease relapse and improve survival in CDI (Clostridium difficile infection)[5].
临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT00437580 Vancomycin Resistant Enterococ... 展开 >>cus Intestinal Carriage 收起 << Phase 4 Unknown August 2009 France ... 展开 >> Service des Maladies infectieuses et tropicales Recruiting Hôpital Gabriel Montpied, Clermont-Ferrand, France, 63003 收起 <<
NCT00295178 Cellulitis Phase 4 Completed - United States, Georgia ... 展开 >> Joseph Still Research Foundation Augusta, Georgia, United States, 30909 收起 <<
NCT01661361 - Unknown December 2012 -
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

0.69mL

0.14mL

0.07mL

3.45mL

0.69mL

0.35mL

6.90mL

1.38mL

0.69mL

参考文献

[1]Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis. 2006 Jan 1;42 Suppl 1:S35-9.

[2]Watanakunakorn C. Mode of action and in-vitro activity of vancomycin. J Antimicrob Chemother. 1984 Dec;14 Suppl D:7-18.

[3]Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis. 2006;42 Suppl 1:S35‐S39

[4]Watanakunakorn C. Mode of action and in-vitro activity of vancomycin. J Antimicrob Chemother. 1984;14 Suppl D:7‐18

[5]Warren CA, van Opstal EJ, Riggins MS, et al. Vancomycin treatment's association with delayed intestinal tissue injury, clostridial overgrowth, and recurrence of Clostridium difficile infection in mice. Antimicrob Agents Chemother. 2013;57(2):689‐696